MedImmune acquires Ann Arbor start-up AlphaCore Pharma
MedImmune has acquired Ann Arbor-based AlphaCore Pharma, creating another exit for a local up-and-coming start-up. MedImmune, the global biologics research and development arm of AstraZeneca, has not disclosed the acquisition price nor its intentions on whether to keep the start-up in Tree Town. Tracy Rossin, director of corporate public relations for MedImmune, did write in an email that the company does "not have plans to expand its operations/workforce in Ann Arbor." She does add that her firm is "planning to incorporate AlphaCore Pharma into the larger AstraZeneca organization." The 5-year-old biotechnology company is developing a recombinant human lecithin-cholesterol acyltransferase enzyme. The enzyme in the bloodstream is a key component in the reverse cholesterol transport system, which is thought to play a major role in driving the removal of cholesterol from the body and may be critical in the management of high-density lipoprotein (HDL) cholesterol levels. AlphaCore Pharma completed a clinical study last year with encouraging results, Brinkeroff says. That made the start-up and its eight-person team an attractive acquisition target, and Brinkeroff says MedImmune is a great partner to continue the development of the enzyme. "They have a deep experience in developing biological products," Brinkeroff says. "They're an ideal partner to hand off to." Source: Bill Brinkeroff, president of AlphaCore Pharma and Tracy Rossin, director of corporate public relations for MedImmune Writer: Jon Zemke Read more about Metro Detroit's growing entrepreneurial ecosystem at SEMichiganStartup.com.
MedImmune has acquired Ann Arbor-based AlphaCore Pharma, creating another exit for a local up-and-coming start-up.
MedImmune, the global biologics research and development arm of AstraZeneca, has not disclosed the acquisition price nor its intentions on whether to keep the start-up in Tree Town. Tracy Rossin, director of corporate public relations for MedImmune, did write in an email that the company does “not have plans to expand its operations/workforce in Ann Arbor.” She does add that her firm is “planning to incorporate AlphaCore Pharma into the larger AstraZeneca organization.”
The 5-year-old biotechnology company is developing a recombinant human lecithin-cholesterol acyltransferase enzyme. The enzyme in the bloodstream is a key component in the reverse cholesterol transport system, which is thought to play a major role in driving the removal of cholesterol from the body and may be critical in the management of high-density lipoprotein (HDL) cholesterol levels.
AlphaCore Pharma completed a clinical study last year with encouraging results, Brinkeroff says. That made the start-up and its eight-person team an attractive acquisition target, and Brinkeroff says MedImmune is a great partner to continue the development of the enzyme.
“They have a deep experience in developing biological products,” Brinkeroff says. “They’re an ideal partner to hand off to.”
Source: Bill Brinkeroff, president of AlphaCore Pharma and Tracy Rossin, director of corporate public relations for MedImmune
Writer: Jon Zemke
Read more about Metro Detroit’s growing entrepreneurial ecosystem at SEMichiganStartup.com.
Related Articles
AI’s impact in Washtenaw County, from tech boom to data centers
Our new three-part series digs into AI’s impacts in Ann Arbor’s tech industry, its utilization in Washtenaw County’s educational world, and the ongoing debate about data centers in several Washtenaw County communities.
Ypsi selected to join downtown revitalization program with emphasis on small manufacturers
Ypsilanti is one of six communities participating in Recast City’s Recast Leaders program, which is focused on strengthening local economies through small-scale manufacturing and product-based businesses.
Data centers in Washtenaw County: Economic boon or environmental liability?
Data center developers and advocates tout their projects as responsible, job-creating economic development engines, but many residents are opposing what they see as threats to their utility bills and the environment.
